Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Global opioids market dominated by the severe pain sector

Global opioids market dominated by the severe pain sector


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2013-01-10 13:27:30 - Global opioids market dominated by the severe pain sector

The global opioids market is currently very broad, with a varied product portfolio. Opioid analgesics are used in the treatment of patients that experience pain because of a number of underlying physiological reasons. For this reason, the severe pain sector is dominated by opioid drugs.In the late 1990s, a perfect storm hit the medical community. The pharmaceutical industry started promoting new opioid formulations for chronic pain conditions, which, when used properly, could be very effective.At the same time, and based on previous success in the surgical, cancer, and palliative care settings, a school of thought formed among pain specialists that opioid analgesics could be used effectively to treat chronic pain -- what many clinicians recall as a genuine attempt at

 

 

more compassionate pain management.Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in opioid abuse and dependency.Over the last few years, the growing concern over opioid abuse has resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift towards developing abuse-resistant formulations of extended-release opioid analgesics, including both novel products and reformulations of existing ones.Since the launch of the first abuse-resistant product, Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have been brought to the market. While abuse-resistant formulations do not confer any clinical benefits, they have become an essential differentiating factor in the current market environment in order ensure that products remain competitive for the future. The current developmental pipeline of opioid products for the management of a range of painful conditions is very small compared to the total revenue and patient pool for the existing products. This is indicative of a very low level of innovation and a high level of market saturation.A total of 54 monotherapies and combination opioid-based therapies that are currently being tested for the treatment of acute and chronic pain, as well as for osteoarthritic, neuropathic, and post-operative pain.For more information on the global opioids market, see the latest research: Global Opioids MarketFollow us on Twitter @CandMResearch

Click for news details: www.companiesandmarkets.com/News/Healthcare-and-Medical/Global-o ..

Browse all Healthcare and Medical C&M News www.companiesandmarkets.com/News/Healthcare-and-Medical/?aCode=f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser